CAC
GILD icon

Cowen and Company’s Gilead Sciences GILD Stock Holding History

Cowen and Company’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$1K – 684
2022
Q1 		$1K Buy
+10,000
New +$639K ﹤0.01% 588
2020
Q2 		– Sell
-14,000
Closed -$98K – 421
2020
Q1 		$98K Buy
+14,000
New +$967K 0.02% 247

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cowen and Company's GILD Position: Q2 2020 in Review

Cowen and Company sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 2,222 shares — an estimated $166K sold.

Cowen and Company first reported a position in GILD in Q1 2020 and held it in 1 quarter. The position peaked at $166K in Q1 2020. 1,626 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

  • Cowen and Company reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
  • Cowen and Company sold 2,222 Gilead Sciences shares in Q2 2020, an estimated $166K.
  • Cowen and Company first reported a position in Gilead Sciences in Q1 2020 and held it in 1 quarter.
  • Cowen and Company's Gilead Sciences position peaked at $166K in Q1 2020.
  • 1,626 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Cowen and Company's 13F filing for Q2 2020, filed 13 Aug 2020.